Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36210 LiqTech International, Inc. (Exact name of registrant as specified in its charter) Nevada 20-1431677 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 GLOBAL GAS CORPORATION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-39819 (Exact name of registrant as specified in its charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 001-39819 GLOBAL GAS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42368 RISING DRAGON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-42368 RISING DRAGON ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands N/A (State ...

Financial Performance - Research & Development Revenue for FY 2024 was $29.6 million, a 63.5% increase from $18.1 million in FY 2023[12] - The net loss for FY 2024 was $(15.3) million, or $(0.85) per share, compared to a net loss of $(20.9) million, or $(1.48) per share, for FY 2023[17] - Gross profit for the year ended December 31, 2024, was $13,274,000, up 68% from $7,880,000 in 2023[31] - Operating loss decreased to $6,582,000 for the year ended December 31, 2024, compared to $12,984,000 in 2023, indicating improved operational efficiency[31] - Net loss for the year ended December 31, 2024, was $15,315,000, a reduction from $20,854,000 in 2023, reflecting a 27% improvement[31] - Basic and diluted net loss per share for 2024 was $0.85, down from $1.48 in 2023, showing a significant reduction in loss per share[31] - Total comprehensive loss for the year ended December 31, 2024, was $15,324,000, compared to $20,842,000 in 2023, reflecting a 27% decrease[31] - Cash used in operating activities for the year ended December 31, 2024, was $9,198,000, an improvement from $13,240,000 in 2023[33] - Net cash provided by financing activities in 2024 was $9,575,000, compared to $3,844,000 in 2023, indicating increased financing support[33] - The company ended 2024 with cash of $5,157,000, up from $4,790,000 at the beginning of the year[33] Revenue Projections - The Company expects to realize its first commercial product revenue in the second half of 2025, with a forecasted revenue of approximately $21.5 million for FY 2025[19] Research and Development - The Company has a multi-year, non-dilutive BARDA PBS contract valued at up to $150 million, with an initial award of approximately $54.9 million[4] - Research and development revenue for Q4 2024 was $7,604,000, a 44% increase from $5,287,000 in Q4 2023[31] - The Burn Validation Study involved 160 patients at 14 burn centers across the US, making it one of the largest burn studies conducted[9] - The Company plans to submit regulatory filings for the DeepView System for burns in the first half of 2025[3] Product Performance - The DeepView System achieved an image-wise sensitivity score of 86.6%, significantly outperforming burn physicians' clinical judgment annotation score of 40.8%[5] Contractual Agreements - The Company completed an equity financing and long-term debt transaction, raising $11.2 million to support its objectives[16] Margins - The gross margin for FY 2024 rose to 44.9% from 43.6%, reflecting the expansion of work under the BARDA PBS contract[13] Cash Position - As of December 31, 2024, cash was $5.2 million, with total current assets amounting to $10.1 million[29]

(MARK ONE) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42414 Dynamix Corporation (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 00-0000000 (State or other jurisdiction of ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission file number: 001-42414 (MARK ONE) FORM 10-Q (I.R.S. Employer Identification No.) 1980 Post Oak Blvd., Suite 100 PMB 6373 Houston, TX, 77056 (Address of principal executive offic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41934 FibroBiologics, Inc. (Exact name of registrant as specified in its charter) Delaware 86-3329066 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to NORTECH SYSTEMS INCORPORATED Commission file number 0-13257 Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 State of Incorporation: Minnesota IRS Employer Identification No. 41-1681094 Executive Offices ...